Holen Sie sich die Stockscreener-App
50.39
0.34%
0.17
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary - GlobeNewswire Inc.
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies - TradingView — Track All Markets
GSK (NYSE:GSK) Lowered to “Underweight” Rating by Barclays - Defense World
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK - Sahm
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
The Truth About GSK plc (ADR): Viral Hype Or Sneaky Safe Bet For Your Portfolio? - AD HOC NEWS
GSK plc (ADR): Defensive Giant Or Underestimated Comeback Story? - AD HOC NEWS
The Truth About GSK plc (ADR): Is Wall Street Sleeping on This Pharma Beast? - AD HOC NEWS
GSK plc (ADR): Defensive Pharma Heavyweight Tests Investor Patience As Street Turns Selectively Bull - AD HOC NEWS
The Truth About GSK plc (ADR): Is This ‘Boring’ Stock Quietly Becoming a Power Play? - AD HOC NEWS
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
The Truth About GSK plc (ADR): Is Wall Street Sleeping On This Pharma Beast? - AD HOC NEWS
New Report Calls Achieve Life's Cytisinicline Best Therapy To Quit Smoking - Sahm
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally - ts2.tech
The Market Is All In on the Magnificent Seven. Where Should Investors Look Next? - Morningstar
HSBC Sees Pharma Poised to Outperform in 2026, Lifts GSK Target - Finviz
Bard Financial Services Inc. Purchases 23,400 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Price History & Data - Traders Union
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of “Hold” by Brokerages - Defense World
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK - Sahm
Douglas Lane & Associates LLC Sells 196,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Sahm
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc - ts2.tech
FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year - Sahm
GSK (NYSE:GSK) Major Shareholder Plc Gsk Purchases 1,470,000 Shares - Defense World
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms - ts2.tech
GSK (NYSE:GSK) Major Shareholder Purchases 1,470,000 Shares - MarketBeat
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU - Finviz
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead - ts2.tech
GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus - ts2.tech
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back - Sahm
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea - Finviz
GSK (GSK) Scores Win in the Form of Lung Cancer Drug's Orphan Drug Designation - Finviz
GSK (GSK) Scores Win in the Form of Lung Cancer Drug’s Orphan Drug Designation - Insider Monkey
GSK (NYSE:GSK) Share Price Passes Above 200-Day Moving Average – Here’s Why - Defense World
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer - Finviz
Is GSK PLC Gaining or Losing Market Support? - Sahm
13 Best ADR Stocks to Invest In - Insider Monkey
Best International Companies to Own: 2026 Edition - Morningstar
J.P. Morgan Maintains a Sell Rating on GSK plc (GSK) - Finviz
Here's Why GSK (GSK) is a Strong Value Stock - Yahoo Finance
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating - ts2.tech
1.87%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):